Centre National De La Recherche Scientifique

Université De Nice Sophia Antipolis

Medincell

Centre National De La Recherche Scientifique-Cnrs

Université Nice Sophia Antipolis

Jean Mazella

Catherine Louise Heurteaux

Marc Borsotto

Georges Gaudriault

Alaeddine Djillani

Sébastien Moreno

Mariel Pietri

Hamid Moha Ou Maati

Julie Veyssiere

Olivier Petrault

Catherine Widmann

Sebastien Moreno

Catherine Heurteaux

Disclosed are new peptides derived from the neurotensin receptor 3 (NTSR3), and to their use, particularly in the treatment of various diseases, especially depression.

Peptides derived from the propeptide NTSR3 and their use in the treatment of depression

Compositions, pharmaceutical compositions and biodegradable pharmaceutical compositions containing at least one analog of spadin or at least one analog of a propeptides of spadin or mixtures thereof are described. Methods for treating depression using the analogs of spadin or analogs of propeptides of spadin or mixtures thereof, as well as methods for blocking TREK-1 channel activity are also disclosed.

Retro-inverso analogs of spadin display increased antidepressant effects

The invention relates to a peptide derived from neurotensin receptor 3 (NTSR3), and to the use thereof in the treatment of psychiatric diseases. The present invention particularly relates to the use of this peptide for producing a drug, such as an antidepressant. The peptide of the invention is characterized in that the sequence thereof is the attached SEQ ID No. 2. The present invention can be used in the fields of the pharmaceutical industry and particularly in the field of drug development for treating psychiatric diseases. The present invention can also be used in the development of a novel antidepressant. It can also be used for example, in the treatment of pain and inflammations.

Peptide derived from neurotensin receptor 3 and use thereof in the treatment of psychiatric diseases

Growing community of inventors

Biot, France

Jean Mazella